Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
May 1st, 2007
Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation of data by researchers at Loma Linda University Medical Center, National Jewish Medical and Research Center and Duke University showing that one of the Company's metalloporphyrin antioxidants, AEOL 10113, demonstrated protection of healthy normal cells in mice with prostate tumor cells treated with radiation therapy. The study also showed that the compound did not interfere with the tumor destruction effects of the radiation therapy. Researchers reported a statistically significant decrease in tumor growth in animals that received radiation alone (p less than 0.05, days 9, 11-14); and in animals that...
Source: Cancer Weekly (2007-05-01)
|
